Expression of the hTERT gene in patients with B-cell chronic lymphocytic leukemia

Authors: R. Plachý ;  J. Pavlíček ;  M. Jarošová ;  T. Papajík
Authors‘ workplace: Hemato-onkologická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci
Published in: Transfuze Hematol. dnes,15, 2009, No. 1, p. 10-12.
Category: Comprehensive Reports, Original Papers, Case Reports


B-cell chronic lymphocytic leukemia (B-CLL) is clinically heterogeneous disease. Therefore it is very important to identify all reliable molecular and cellular markers to predict the tendency for disease progression. One of the promising prognostic markers seems to be expression of hTERT gene, which encodes catalytic subunit of human telomerase. We performed real-time reverse transcription PCR to quantitate the amount of hTERT transcripts in mononuclear blood cells from 47 B-CLL patients. We used ABL gene as a housekeeping gene.We compared the expression of hTERT to the IgVH mutational status. Median of hTERT expression was fourfold higher in the IgVH unmutated group than in the IgVH mutated group (p<0.00001). The level of hTERT expression discriminated the IgVH unmutated from IgVH mutated B-CLL in 87% cases. Our results suggests that hTERT expression strongly correlates with IgVH mutational status. Full understanding of the hTERT role in pathogenesis and progression of B-CLL could contribute to better prognostic stratification of patients with B-CLL.

Key words:
reverse telomerase, hTERT, B-CLL, mutational status of IgVH


1. Huh HJ, Huh JW, Yoo ES et al. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol 2005; 79: 267–73.

2. Streutker CJ, Thorner P, Fabricius N et al. Telomerase activity as a prognostic factor in neuroblastomas. Pediatr Dev Pathol 2001; 4: 62–7.

3. Terrin L, Trentin L, Degan M et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome. Leukemia 2007; 21: 965–972.

4. van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317.

5. Thompsett AR, Ellison DW, Stevenson FK, et al. VH Gene Sequences From Primary Central Nervous System Lymphomas Indicate Derivation From Highly Mutated Germinal Center B Cells With Ongoing Mutational Activity. Blood 1999; 94: 1738–1746.

6. Bechter OE, Eisterer W, Pall G. Telomere length and telomerase activity predict survival in patients with B-cell chronic lymphocytic leukemia. Cancer Res 1998; 58: 4918–4922.

7. Damle RN, Batliwalla FM, Ghiotto F. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by Ig V gene mutations. Blood 2004; 103: 375–382.

8. Tchirkov A, Chaleteix C, Magnac C, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol., 2004; 15: 1476–1480.

9. Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2003; 88: 593–598.

10. Cao Y, Li H, Deb S, et al. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002; 21: 3130–3138.

11. Deville L, Hillion J, Lanotte M, et al. Diagnostics, prognostic and therapeutic exploitation of telomeres and telomerase in leukemias. Curr Pharm Biotechnol 2006; 7: 171–83.

Haematology Internal medicine Clinical oncology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account